Budget impact analysis of including biosimilar adalimumab on formulary: A United States payer perspective
{{output}}
Background: The biosimilar market is growing rapidly, as evidenced by 41 approvals and 37 launches to date. As adalimumab biosimilars launch in the United States, competition among biosimilar and reference adalimumab will likely ... ...
